Adverse events associated with mTOR inhibitors

Expert Opinion on Drug Safety

Volumn 12, Issue 2, 2013, Pages 177-186

  Pallet, Nicolas ^a   Legendre, Christophe ^b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Adverse effects; Everolimus; Kidney; MTOR; Rapamycin; Side effects; Sirolimus; Transplantation

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; CHOLESTEROL; CLOBETASOL PROPIONATE; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; RIDAFOROLIMUS; STEROID; TACROLIMUS; TEMSIROLIMUS; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACNE; ADVANCED CANCER; APHTHOUS STOMATITIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; DELAYED GRAFT FUNCTION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ERYTHRODERMA; FOLLICULITIS; GENERALIZED EDEMA; GRAFT REJECTION; HEMODIALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; IN-STENT RESTENOSIS; INFLAMMATION; INTERSTITIAL PNEUMONIA; KIDNEY CANCER; KIDNEY TRANSPLANTATION; LEUKOCYTOCLASTIC VASCULITIS; LYMPHOCELE; MALE FERTILITY; MANTLE CELL LYMPHOMA; METABOLIC DISORDER; MICROCYTIC ANEMIA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; PNEUMONIA; PROTEINURIA; RASH; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUBEROUS SCLEROSIS; WOUND HEALING IMPAIRMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DYSLIPIDEMIAS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROTEIN KINASE INHIBITORS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84874147739     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.752814     Document Type: Review

References (94)

1. Martel R R, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977;55(1):48-51 (Pubitemid 8061941)
2. Houchens D P, Ovejera A A, Riblet SM, Slagel DE. Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol 1983;19(6):799-805 (Pubitemid 13058375)
3. Heitman J, Movva N R, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991;253(5022):905-9 (Pubitemid 21917235)
4. Cafferkey R, Young PR, McLaughlin M M, et al. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol Cell Biol 1993;13(10):6012-23 (Pubitemid 23292596)
5. Sabatini D M, Erdjument-Bromage H, Lui M, et al. RAFT1: B mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994;78(1):35-43 (Pubitemid 24228298)
6. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149(2):274-93
7. Laplante M, Sabatini DM. mTOR Signaling. Cold Spring Harb Perspect Biol 2011;4(2): Pii: B011593
8. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28(10):721-6
9. Yip C K, Murata K, Walz T, et al. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell 2010;38(5):768-74
10. Brown E J, Beal P A, Keith C T, et al. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 1995;377(6548):441-6
11. Brunn G J, Hudson C C, Sekulic A, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997;277(5322):99-101 (Pubitemid 27450655)
12. Burnett P E, Barrow R K, Cohen NA, et al. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 1998;95(4):1432-7 (Pubitemid 28103409)
13. Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 2008;14(5):1286-90 (Pubitemid 351413905)
14. Mita M, Sankhala K, Abdel-Karim I, et al. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs 2008;17(12):1947-54
15. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 1997;64(1):36-42 (Pubitemid 27327197)
16. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: B new generation of mTOR inhibitors. Nat Rev Drug Discov 2012;10(11):868-80
17. Yatscoff R W, LeGatt DF, Kneteman NM. Therapeutic monitoring of rapamycin: B new immunosuppressive drug. Ther Drug Monit 1993;15(6):478-82 (Pubitemid 23347236)
18. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: B randomised multicentre study. The Rapamune US Study Group. Lancet 2000;356(9225):194-202 (Pubitemid 30446974)
19. Kreis H, Cisterne J M, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000;69(7):1252-60 (Pubitemid 30238708)
20. Kahan B D, Kaplan B, Lorber M I, et al. RAD in de novo renal transplantation: Comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001;71(10):1400-6 (Pubitemid 32507112)
21. Serruys P W, Regar E, Carter AJ. Rapamycin eluting stent: The onset of a new era in interventional cardiology. Heart 2002;87(4):305-7 (Pubitemid 34270933)
22. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293(17):2126-30 (Pubitemid 40617065)
23. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5(8):671-88 (Pubitemid 44151605)
24. Bissler J J, McCormack F X, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358(2):140-51
25. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81 (Pubitemid 46849157)
26. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27(23):3822-9
27. Motzer R J, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: B double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
28. Yao J C, Shah M H, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):514-23
29. O'Reilly K E, Rojo F, She Q B, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66(3):1500-8 (Pubitemid 43259931)
30. Choo A Y, Yoon S O, Kim S G, et al. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-Type-specific repression of mRNA translation. Proc Natl Acad Sci USA 2008;105(45):17414-19
31. Groth C G, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999;67(7):1036-42 (Pubitemid 29200856)
32. Kahan B. Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: Etiology, pathogenesis and treatment. Expert Opin Drug Saf 2011;10(5):727-49
33. Holdaas H, Midtvedt K, Asberg A. A drug safety evaluation of everolimus in kidney transplantation. Expert Opin Drug Saf 2012;11(6):1013-22
34. Bukowski RM. Temsirolimus: B safety and efficacy review. Expert Opin Drug Saf 2012;11(5):861-79
35. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001;71(2):271-80 (Pubitemid 32126112)
36. Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: Results at three years. Transplantation 2003;75(12):2048-53 (Pubitemid 36793291)
37. Lorber M I, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: B 3-year randomized, multicenter, phase III study. Transplantation 2005;80(2):244-52 (Pubitemid 41061682)
38. Napoli K L, Wang M E, Stepkowski SM, Kahan BD. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: Evidence for pharmacokinetic interactions. Ther Drug Monit 1998;20(2):123-33 (Pubitemid 28163193)
39. Podder H, Stepkowski S M, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001;12(5):1059-71 (Pubitemid 32378348)
40. Anglicheau D, Pallet N, Rabant M, et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 2006;70(6):1019-25 (Pubitemid 44344071)
41. Hong J C, Kahan BD. A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function. Transplantation 2001;71(9):1320-8 (Pubitemid 32507156)
42. McTaggart R A, Gottlieb D, Brooks J, et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003;3(4):416-23 (Pubitemid 36560092)
43. Pallet N, Thervet E, Le Corre D, et al. Rapamycin inhibits human renal epithelial cell proliferation: Effect on cyclin D3 mRNA expression and stability. Kidney Int 2005;67(6):2422-33 (Pubitemid 41623406)
44. Lieberthal W, Fuhro R, Andry C C, et al. Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001;281(4):F693-706
45. Dantal J, Berthoux F, Moal M C, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 2010;23(11):1084-93
46. Diekmann F, Andres A. Oppenheimer F. mTOR inhibitor-Associated proteinuria in kidney transplant recipients. Transplant Rev (Orlando) 2012 Jan;26(1):27-9
47. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of de-novo kidney transplants: Bn open-label, randomised, controlled trial. Lancet 2011;377(9768):837-47
48. Wali R K, Mohanlal V, Ramos E, et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007;7(6):1572-83 (Pubitemid 46776263)
49. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: ConcePTstudy. Am J Transplant 2009;9(5):1115-23
50. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003;35(3 Suppl):52S-7S (Pubitemid 36547915)
51. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004;4(11):1869-75 (Pubitemid 39434449)
52. Buchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007;7(11):2522-31 (Pubitemid 47561618)
53. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008;14(9):931-8
54. Godel M, Hartleben B, Herbach N, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 2011 Jun;121(6):2197-209
55. Letavernier E, Pe'raldi M N, Pariente A, et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005;80(9):1198-203 (Pubitemid 41746797)
56. Robson M, Cote I, Abbs I, et al. Thrombotic micro-Angiopathy with sirolimus-based immunosuppression: Potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 2003;3(3):324-7 (Pubitemid 36407052)
57. Saikali J A, Truong L D, Suki WN. Sirolimus may promote thrombotic microangiopathy. Am J Transplant 2003;3(2):229-30 (Pubitemid 36323121)
58. Reynolds J C, Agodoa L Y, Yuan CM, Abbott KC. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003;42(5):1058-68 (Pubitemid 37322923)
59. Sofroniadou S, Goldsmith D. Mammalian target of rapamycin (mTOR) inhibitors: Potential uses and a review of haematological adverse effects. Drug Saf 2011;34(2):97-115
60. Hong J C, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: Risk factors, incidence, progression, and management. Transplantation 2000;69(10):2085-90 (Pubitemid 30395038)
61. Webster A C, Lee V W, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: B systematic review and meta-Analysis of randomized trials. Transplantation 2006;81(9):1234-48
62. Thaunat O, Beaumont C, Chatenoud L, et al. Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 2005;80(9):1212-19 (Pubitemid 41746799)
63. Thaunat O, Beaumont C, Lechaton S, et al. Late introduction of sirolimus induces anemia in renal transplant recipients. Transplantation 2007;83(9):1283 (Pubitemid 46743695)
64. Campistol J M, de Fijter JW, Flechner S M, et al. mTOR inhibitor-Associated dermatologic and mucosal problems. Clin Transplant 2010;24(2):149-56
65. Mahe E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005;79(4):476-82 (Pubitemid 40280181)
66. Dereure O. Skin reactions related to treatment with anticytokines, membrane receptor inhibitors and monoclonal antibodies. Expert Opin Drug Saf 2003;2(5):467-73
67. Mahe E, Morelon E, Lechaton S, et al. Acne in recipients of renal transplantation treated with sirolimus: Clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol 2006;55(1):139-42 (Pubitemid 43867022)
68. Watson C J, Firth J, Williams P F, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005;5(10):2496-503
69. Toso C, Meeberg G A, Bigam D L, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: Long-Term outcomes and side effects. Transplantation 2007;83(9):1162-8 (Pubitemid 46743675)
70. van Gelder T, ter Meulen C G, Hene R, et al. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003;75(6):788-91 (Pubitemid 36373448)
71. Hardinger K L, Cornelius LA, Trulock EP III, Brennan DC. Sirolimus-induced leukocytoclastic vasculitis. Transplantation 2002;74(5):739-43
72. Nagarajan S, Friedrich T, Garcia M, et al. Gastrointestinal leukocytoclastic vasculitis: Bn adverse effect of sirolimus. Pediatr Transplant 2005;9(1):97-100 (Pubitemid 40238972)
73. Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-Transplant recipients. N Engl J Med 2000;343(3):225-6 (Pubitemid 30489228)
74. Weiner S M, Sellin L, Vonend O, et al. Pneumonitis associated with sirolimus: Clinical characteristics, risk factors and outcome-A single-centre experience and review of the literature. Nephrol Dial Transplant 2007;22(12):3631-7 (Pubitemid 350212488)
75. Morelon E, Stern M, Israel-Biet D, et al. Characteristics of sirolimus-Associated interstitial pneumonitis in renal transplant patients. Transplantation 2001;72(5):787-90 (Pubitemid 32879846)
76. Duran I, Siu L L, Oza A M, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006;42(12):1875-80 (Pubitemid 44149096)
77. Cho D, Signoretti S, Regan M, et al. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007;13(2 PT2):758s-63s
78. Rehm B, Keller F, Mayer J, Stracke S. Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant Proc 2006;38(3):711-13
79. Maroto J P, Hudes G, Dutcher J P, et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 2011;29(13):1750-6
80. Champion L, Stern M, Israel-Biet D, et al. Brief communication: Sirolimus-Associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 2006;144(7):505-9 (Pubitemid 46780673)
81. Brattstrom C, Wilczek H, Tyden G, et al. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998;65(9):1272-4 (Pubitemid 28224351)
82. Johnston O, Rose C L, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19(7):1411-18
83. Vodenik B, Rovira J, Campistol JM. Mammalian target of rapamycin and diabetes: What does the current evidence tell us? Transplant Proc 2009;41(6 Suppl):S31-8
84. Soefje S A, Karnad A, Brenner AJ. Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol 2011;6(2):125-9
85. Huyghe E, Zairi A, Nohra J, et al. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: Bn overview. Transpl Int 2007;20(4):305-11
86. Zuber J, Anglicheau D, Elie C, et al. Sirolimus may reduce fertility in male renal transplant recipients. Am J Transplant 2008;8(7):1471-9 (Pubitemid 351989493)
87. Timokhina I, Kissel H, Stella G, Besmer P. Kit signaling through PI 3-kinase and Src kinase pathways: Bn essential role for Rac1 and JNK activation in mast cell proliferation. EMBO J 1998;17(21):6250-62 (Pubitemid 28497798)
88. Dean P G, Lund W J, Larson T S, et al. Wound-healing complications after kidney transplantation: B prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004;77(10):1555-61 (Pubitemid 38703037)
89. Benavides C, Mahmoud K H, Knight R, et al. Rabbit antithymocyte globulin: B postoperative risk factor for sirolimus-Treated renal transplant patients? Transplant Proc 2005;37(2):822-6 (Pubitemid 40590713)
90. Langer R M, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2002;74(6):804-8
91. Rogers C C, Hanaway M, Alloway RR, et al. Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy. Transplant Proc 2005;37(2):795-7 (Pubitemid 40590703)
92. Albano L, Berthoux F, Moal M C, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009;88(1):69-76
93. Nashan B, Citterio F. Wound healing complications and the use of Mammalian target of rapamycin inhibitors in kidney transplantation: B critical review of the literature. Transplantation 2012;94(6):547-61
94. Saemann M D, Haidinger M, Hecking M, et al. The multifunctional role of mTOR in innate immunity: Implications for transplant immunity. Am J Transplant 2009;9(12):2655-61